Anagrelide hydrochloride
-
Anagrelide hydrochloride
structure -
-
CAS No:
58579-51-4
-
Formula:
C10H7Cl2N3O.ClH
-
Chemical Name:
Anagrelide hydrochloride
-
Synonyms:
Imidazo[2,1-b]quinazolin-2(3H)-one,6,7-dichloro-1,5-dihydro-,hydrochloride (1:1);Imidazo[2,1-b]quinazolin-2(3H)-one,6,7-dichloro-1,5-dihydro-,monohydrochloride;BL 4162A;Anagrelide hydrochloride;Agrelin;BMY 26538-01;Agrylin;6,7-Dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one Hydrochloride
- Categories:
-
CAS No:
Description
Anagrelide Hydrochloride(BL4162A) is a drug used for the treatment of essential thrombocytosis.Target: PDEAnagrelide hydrochloride is an oral imidazoquinazoline agent that has been shown to reduce elevated platelet counts and the risk of thrombosis in patients with thrombocythaemia in various myeloproliferative disorders (MPD). It is currently approved by the FDA as oral treatment for essential thrombocythaemia (ET) and thrombocythaemia associated with polycythaemia vera (PV). Anagrelide
Anagrelide hydrochloride is the hydrochloride salt of anagrelide. It has a role as an antifibrinolytic drug and a platelet aggregation inhibitor. It contains an anagrelide.|Anagrelide Hydrochloride is the hydrochloride salt of a synthetic quinazoline derivative, Anagrelide Hydrochloride reduces platelet production through a decrease in megakaryocyte maturation. Anagrelide inhibits cyclic AMP phosphodiesterase, as well as ADP- and collagen-induced platelet aggregation. At therapeutic doses, it does not influence white cell counts or coagulation parameters. Anagrelide is used for treatment of essential thrombocythemia to reduce elevated platelet counts and the risk of thrombosis. (NCI04)
Anagrelide hydrochloride Basic Attributes
292.55
290.973297
1308068-626-2
VNS4435G39
759170|724577
DTXSID0046725
C28826
L01XX35
2933990090
Characteristics
44.7
white to beige
1.77g/cm3
>280 °C
181.5ºC
DMSO: soluble 1mg/mL, clear (warmed)
Desiccate at +4°C
6.8X10-10 mm Hg at 25 deg C /Estimated/
147.9 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]
Safety Information
NONH for all modes of transport
3
22-36/37/38
26
Xn
P261-P305 + P351 + P338
H302-H315-H319-H335
|Danger|H302 (82.35%): Harmful if swallowed [Warning Acute toxicity, oral]|P201, P202, P261, P264, P270, P271, P280, P281, P301+P312, P302+P352, P304+P340, P305+P351+P338, P308+P313, P312, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, and P501|Aggregated GHS information provided by 51 companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Drug Information
Anagrelide is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.An at-risk patientAn at-risk essential thrombocythaemia patient is defined by one or more of the following features:>60 years of age ora platelet count >1,000 x 10⁹/l ora history of thrombo-haemorrhagic events.
Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. (See all compounds classified as Fibrinolytic Agents.)|Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (See all compounds classified as Platelet Aggregation Inhibitors.)
6,7-dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3H)-one hydrochloride
Anagrelide hydrochloride Use and Manufacturing
In a 100 ml round-bottom flask anagrelide (0.50 g, 1.952 mmol) was stirred in DMSO (4 ml) to give a white suspension. The mixture was heated on an oil bath. At 50°C, concentrated hydrochloric acid (0.22 ml, 2.48 mmol) was added. An almost clear solution was obtained after further heating. Ethanol (9 ml) was added, and the clear yellow/orange solution was allowed to cool to room temperature. At 40°C (internal temperature), the solution was seeded with anagrelide hydrochloride crystals. A white suspension was obtained. The suspension was filtered over a glass filter, and the crystalline solid was washed with ethanol, and dried on the air, giving anagrelide hydrochloride (255 mg, 0.863 mmol, 44.2 percent yield) as a white crystalline solid.
Signal Transduction Agents, Potent PDE3 inhibitor
Human drugs -> Anagrelide Mylan -> EMA Drug Category|Antineoplastic agents -> Human pharmacotherapeutic group|Human drugs -> Rare disease (orphan)|Human Drugs -> FDA Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) -> Active Ingredients
Computed Properties
Molecular Weight:292.5
Hydrogen Bond Donor Count:2
Hydrogen Bond Acceptor Count:2
Exact Mass:290.973295
Monoisotopic Mass:290.973295
Topological Polar Surface Area:44.7
Heavy Atom Count:17
Complexity:360
Covalently-Bonded Unit Count:2
Compound Is Canonicalized:Yes
Recommended Suppliers of Anagrelide hydrochloride
-
CN
5 YRS
Business licensedTrader Supplier of Intermediates,Building blocks,API,Silicones,Peptides,Lab chemicals,Biochemicals,Pharmaceuticals,Screening Compounds,Food Additives -
CN
4 YRS
Business licensed Certified factoryManufactory Supplier of N-Diethyl-m-toluamide,6-Methyluracil,Anisole,4-Dimethoxybenzoic acid,CS (lacrimator),Daucosterol,N,N-Formylmorpholine,Epichlorohydrin,Tetramethylguanidine,Dimethicone,3
Latest News on Anagrelide hydrochloride
- BMS Over $900 Million to Help Develop Potential 'Best-in-class' SHP2 Inhibitors
- AbbVie's blockbuster product for atopic dermatitis, Upadacitinib, has been approved for marketing in the EU and Japan
- Designing peptide inhibitors for possible COVID-19 treatments
- Chinese scientists discover the inhibitors of SARS-CoV-2
Learn More Other Chemicals
-
4H-1-Benzopyran-4-one, 2-[4-[3-(dibutylamino)propoxy]-3,5-dimethylbenzoyl]-, hydrochloride (1:1)
67652-33-9
-
Cyclopropanecarboxylic acid, 1-amino-2-ethenyl-, ethyl ester, hydrochloride (9CI)
681807-60-3
-
CYCLOPENTYL-(3,4,5-TRIMETHOXY-BENZYL)-AMINE HYDROCHLORIDE
1052525-88-8
-
2-Cyclopropylbenzenemethanamine hydrochloride Formula
118184-64-8
-
Des[4-(2-cycloproylMethoxy)] Betaxolol Hydrochloride Formula
464877-45-0
-
Ethanamine, 2-(decylthio)-, hydrochloride (1:1) Formula
36362-09-1
-
4,7-Dichloro-2-propylquinoline hydrochloride Structure
1204812-22-5
-
6,7-Dichloro-4-hydrazino-2-methylquinoline hydrochloride Structure
1170377-12-4
-
What is 2,8-Diazaspiro[4.5]decan-1-one, 2-[(4-bromophenyl)methyl]-, hydrochloride (1:1)
832710-56-2
-
What is 6,7-Dichloro-4-hydrazinoquinoline hydrochloride
1171843-02-9